|
14.07.2021 13:00:00
|
Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2021 financial results on Wednesday, July 28, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following link
Following the live audio webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 single, dual and triple combination studies. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com
Investor Relations contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2021-results-on-wednesday-july-28-2021-301333441.html
SOURCE Compugen Ltd.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Compugen Ltd.mehr Nachrichten
|
11.03.25 |
NASDAQ Composite Index-Papier Compugen-Aktie: So viel Verlust hätte eine Investition in Compugen von vor 3 Jahren bedeutet (finanzen.at) | |
|
05.03.25 |
Gute Stimmung in New York: NASDAQ Composite steigt schlussendlich (finanzen.at) | |
|
04.03.25 |
NASDAQ-Handel NASDAQ Composite beendet den Dienstagshandel im Minus (finanzen.at) | |
|
04.03.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite am Nachmittag fester (finanzen.at) | |
|
04.03.25 |
NASDAQ Composite Index-Papier Compugen-Aktie: So viel Verlust hätte ein Compugen-Investment von vor einem Jahr eingefahren (finanzen.at) | |
|
25.02.25 |
NASDAQ Composite Index-Wert Compugen-Aktie: So viel Verlust hätte ein Compugen-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
|
18.02.25 |
NASDAQ Composite Index-Papier Compugen-Aktie: So viel Verlust hätte ein Investment in Compugen von vor 5 Jahren eingebracht (finanzen.at) | |
|
11.02.25 |
NASDAQ-Handel NASDAQ Composite zeigt sich zum Handelsende leichter (finanzen.at) |
Analysen zu Compugen Ltd.mehr Analysen
Aktien in diesem Artikel
| Compugen Ltd. | 1,65 | -0,30% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.